Blog

Company News

Industry Trends

Laws Regulations

All Categories >

01

2024-07

Hycells Warmly Congratulates Ucardi on Obtaining Implicit Clinical Approval for Its Innovative CAR-T Therapy for Solid Tumors

On June 28, 2024, the website of the Center for Drug Evaluation (CDE) under the National Medical Products Administration announced that the Investigational New Drug (IND) application for U87 Injection, an innovative drug independently developed by Shanghai Youcardi, has officially been granted tacit approval (Acceptance Number: CXSL2400222), with Trop2-positive advanced malignant tumors as its intended indication.

2024-07-01

He Yousheng

27

2024-06

Small “Life” Makes Sense (7) | Detection Antibodies for Fusion Proteins, Single-Chain Variable Fragments (scFv), and Bispecific Antibody Flexible Linkers (G4S)n

Last year, Hycells launched its blockbuster, universal CAR positivity assay antibody—Anti-G4S linker—which quickly won widespread recognition and collaboration from a growing customer base thanks to its ease of use and high precision. Anti-G4S linker is a universally applicable CAR positivity assay reagent that has been rigorously validated by numerous customers; by eliminating unnecessary and time-consuming steps, it accelerates the drug development process. It is suitable for detecting CARs with G4S linkers targeting any antigen ((G4S)n, where n ≥ 2), as well as for assays involving various antibody types that incorporate (G4S)n (where n ≥ 2). Moreover, it exhibits robust resistance to interference, remaining unaffected by antigen cross-reactivity and delivering more accurate in vivo CAR proportion measurements. Its exceptional sensitivity ensures outstanding detection performance even at very high or very low concentrations.

2024-06-27

He Yousheng

26

2024-06

Hycells New Product | 4-Day Rapid DC Cell Induction Kit

Dendritic cells (DCs) derive their name from the dendritic processes on their surface, which facilitate antigen capture and intercellular communication with other immune cells. As the most potent professional antigen-presenting cells (APCs), dendritic cells efficiently engulf, process, and present antigens. However, DCs are relatively rare in peripheral blood, accounting for only about 1% of peripheral blood mononuclear cells.

2024-06-26

He Yousheng

04

2024-06

Riding the Waves and Pressing On | Hycells’s 2024 Qiandao Lake Team-Building Trip

Qiandao Lake is located in Chun’an County, Zhejiang Province. Constructed in 1959, it is home to China’s first large-scale hydropower station—Xin’anjiang Hydropower Station—which was entirely designed and built using domestically produced equipment. The artificial lake created by the dam serves as a national Class-I water body. Qiandao Lake Scenic Area is not only one of China’s most renowned lake destinations but also one of the country’s premier training bases for canoeing and rowing. With a thousand islands scattered across its waters, Qiandao Lake offers a thousand unique ways for visitors to experience its beauty: cycling around the lake, soaring above the clouds, immersing oneself in romantic flower fields, cruising on a luxury yacht, trying go-karting, or enjoying a water park—its diverse offerings and endless recreational opportunities ensure there’s something for everyone. Some vistas are so unforgettable that even before you’ve fully taken them in, they already linger in your heart.

2024-06-04

He Yousheng

07

2024-05

Meet in Jinling | Shanghai Hycells Biotechnology Co., Ltd. cordially invites you to attend the 2024 IBI EXPO!

Co-hosted by MedSail and Nanjing Biomedical Valley, the 2024 IBI EXPO Biopharmaceutical Innovation Drug Industry Conference focuses on the field of biologic innovative drugs, covering cutting-edge technological areas such as cell therapy, gene therapy, nucleic acid therapeutics, iPSC-based therapies, exosomes, novel antibodies, and organoids.

2024-05-07

He Yousheng

30

2024-04

Hycells New Product | Anti-Payload—MMAE/MMAF/DXD Antibody

Antibody–drug conjugates (ADCs) are an emerging class of targeted therapies for cancer treatment, designed to deliver cytotoxic small-molecule payloads directly to and selectively kill tumor cells. Essentially a form of targeted chemotherapy, ADCs have now advanced to the third generation, with substantial improvements in both safety and efficacy. Technological innovations in this field have primarily focused on the payload, the linker, and the conjugation chemistry, while the engineering and optimization of the payload remain a central focus for enhancing ADC performance.

2024-04-30

He Yousheng
< 1...121314...24 >